The U.S. Food and Drug Administration has approved the first messenger RNA (mRNA) flu vaccine, mFlusiva, developed by Moderna. This approval marks a significant advancement in influenza prevention, particularly for vulnerable populations such as older adults.
Dr. Jeanne Marrazzo, CEO of the Infectious Diseases Society of America, described the approval as a "historic event and incredibly exciting, both scientifically and from a public-health standpoint." Stéphane Bancel, Moderna's CEO, stated that "Flu remains a significant public health challenge, and mFlusiva provides an important new option for America’s seniors."
The mRNA technology behind mFlusiva allows for a more rapid vaccine development process compared to traditional flu vaccines. This new vaccine can be developed in approximately six weeks, utilizing a genetic plug-and-play model that allows for quick adaptation to new viral strains. In contrast, conventional flu vaccines require up to six months for creation, as they involve growing the influenza virus in eggs before processing it for the vaccine.
This faster development cycle is crucial for matching flu vaccines to the specific influenza strains circulating in a given region and time. A better match generally leads to a more effective vaccine in preventing flu and its severe complications, including pneumonia, respiratory distress, and organ failure. These consequences disproportionately affect older individuals, young children, and those with weakened immune systems.
Moderna's mRNA flu vaccine is expected to be available for the upcoming flu season.